Chlorhexidine vs Lactobacillus Plantarum for Oral Care in Intubated ICU Patients

Sponsor
Region Skane (Other)
Overall Status
Completed
CT.gov ID
NCT01105819
Collaborator
County Council of Halland, Sweden (Other), Probi AB (Industry)
100
3
2
93
33.3
0.4

Study Details

Study Description

Brief Summary

Critically ill patients often need ventilatory support through a plastic tube connected to a ventilator. Those patients have a altered microbiological flora in the mouth, oropharynx as well as throughout the intestine. Bacteria that can cause illness are often found in the oropharynx in such patients and measures are taken in order to reduce the risk of secondary infections by those bacteria. In all intensive care patients oral care is provided by the nursing staff aiming at a reduction of the pathogenic species. This is done by a variety measures.

Chlorhexidine (CHX) is an antisepticum with a capability to reduce bacterial counts in the mouth and oropharynx and has been shown to be of value also for intubated patients. It is used frequently throughout the world.

Ventilator-associated pneumonia (VAP) is a costly rather frequent complication to intensive care and mechanical ventilation and is usually caused by aspiration of infected secretions from the oropharynx. CHX has in some studies been shown to reduce the frequency of VAP.

The probiotic bacterium Lactobacillus plantarum 299 has the ability to adhere to the mucosa throughout the gastro-intestinal tract including the mouth and in our pilot study we found that L plantarum had better ability to reduce colonisation with enteric bacteria in the oropharynx than CHX had. Figures not statistical significant so this present study is aiming to get a larger amount of data.

The procedure was found to be safe Hypothesis: Lactobacillus plantarum is better than CHX for the reduction of pathogenic bacteria in the oropharynx in intubated mechanically ventilated patients and consequently has a better potential to reduce the frequency of VAP

Condition or Disease Intervention/Treatment Phase
  • Procedure: Lactobacillus plantarum 299 for oral care
  • Procedure: Chlorhexidine for standard oral care
N/A

Detailed Description

This study is an expansion of a pilot study performed at the ICU Lund University Hospital, Sweden where 50 patients were included (ISRCTN00472141).

Results have been published in Critical Care 2008, 12:R136 The protocol is the same and in this second phase we intend to include 100 patients and results will be summed up.

Three centres are engaged. The results from the pilot study is encouraging and we are aiming at getting statistical significance in the differences in pathogenic findings in the cultures from oropharynx and also better a better basis for the calculation of the number of patients needed to get sufficient power to study difference in VAP frequency.

Study Design

Study Type:
Interventional
Actual Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
A Study Comparing a Suspension of Lactobacillus Plantarum 299 With Chlorhexidine for Oral Care in Intubated Mechanically Ventilated Patients in Intensive Care
Study Start Date :
Apr 1, 2010
Actual Primary Completion Date :
Jan 1, 2016
Actual Study Completion Date :
Jan 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Other: Standard oral care with chlorhexidine

The control group will receive a standard oral care. This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed

Procedure: Chlorhexidine for standard oral care
A The control group will receive the standard oral care of the department (general ICU, Lund University Hospital). This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day

Active Comparator: Lactobacillus plantarum 299

The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day

Procedure: Lactobacillus plantarum 299 for oral care
The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day

Outcome Measures

Primary Outcome Measures

  1. To compare the number and frequency of cultures with pathogenic bacteria and fungi from the oropharynx and tracheal secretions and the spectra of these microbiological species [During study time in connection with the care in the ICU until invasive mechanical ventilation is terminated]

  2. Recovery of Lactobacillus plantarum 299 in tracheal secretions in the active treatment group as an indicator of aspiration [During study time in connection with the care in the ICU until invasive mechanical ventilation is terminated]

Secondary Outcome Measures

  1. SOFA score and Influence on lung function measured as Lung Injury Severity Score [From admission to the ICU til discharge from the ICU]

  2. Difference in emerge of Ventilator Associated Pneumonia [During ICU stay]

  3. Validation of micobiological findings compared to the use of antibiotics [ICU stay + 48 hours]

  4. C-reactive protein and white blood cell counts [From admission to the ICU til discharge from the ICU]

  5. Evaluation of microbiological cultures taken on clinical grounds [ICU-stay + 48 hours]

    We want to examine the possible influence of the added probioticum on the frequence of positive cultures from other sites than those taken per protocol. Samples taken during ICU-stay and 48 hours after discharge from the ICU will be examened The type of species in positive cultures are also of interest. Blood cultures may act as indicator of vascular spread of the studied bacterium. According to the protocol samples for blood cultures are not taken

  6. 28 day mortality [28 days after ICU admission]

  7. 6 months mortality [6 months after ICU admission]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • 18 years or older

  • Critically ill patients anticipated to require mechanical ventilation for at least 24 hours

Exclusion Criteria:
  • Pneumonia as admission diagnosis,

  • Fractures on the facial skeleton or the skull base;

  • Known ulcers in the oral cavity, the oropharynx, or the esophagus

  • Known immune difficency

  • Carrier of HIV or Hepatitis

  • Patient being moribund

Contacts and Locations

Locations

Site City State Country Postal Code
1 Intensive Care Unit, Halmstad Central Hospital Halmstad Sweden SE 301 85
2 Intensive Care Unit, Kristianstad Central hospital Kristianstad Sweden SE 291 85
3 Intensive Care Unit, Lund University Hospital Lund Sweden SE 221 85

Sponsors and Collaborators

  • Region Skane
  • County Council of Halland, Sweden
  • Probi AB

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Bengt Klarin, Consultant, MD, PhD, Region Skane
ClinicalTrials.gov Identifier:
NCT01105819
Other Study ID Numbers:
  • PROHYG 1B
First Posted:
Apr 19, 2010
Last Update Posted:
May 17, 2018
Last Verified:
May 1, 2018
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Keywords provided by Bengt Klarin, Consultant, MD, PhD, Region Skane
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 17, 2018